Medical cannabis has moved from ancient remedies to modern clinical discussions, especially in palliative care. Patients with advanced illness often suffer from multiple symptoms—pain, fatigue, anorexia, anxiety, and sleep disturbances. Traditional medications can add to the burden through side effects and drug interactions, prompting interest in cannabis as a potential multi-symptom therapy.
FDA-Approved Cannabinoid Therapies
While cannabis itself remains federally classified as Schedule I in the U.S., the FDA has approved specific cannabinoid-based medications: – Dronabinol (Marinol, Syndros) – Synthetic THC. Approved for chemotherapy-induced nausea/vomiting (CINV, 1985) and anorexia related to AIDS wasting syndrome (1992). – Nabilone (Cesamet, Canemes) – Synthetic THC analog. Approved for refractory CINV. – Cannabidiol (Epidiolex) – Highly purified plant-derived CBD. Approved for rare pediatric epilepsies (Dravet syndrome, Lennox-Gastaut syndrome). – Nabiximols (Sativex) – A balanced THC:CBD oral spray, widely used in Europe/Canada for MS-related spasticity, but not FDA approved in the U.S.
Clinical Applications in Palliative Care
Evidence suggests cannabinoids may help with: – Cancer-related pain – Some randomized controlled trials (RCTs) show benefit with nabiximols in opioid-refractory pain. – Chemotherapy induced nausea and vomiting(CINV) – Dronabinol and nabilone have efficacy comparable to ondansetron in certain contexts. – Appetite stimulation – Mixed evidence, with modest improvements in appetite but not always in weight gain. – Sleep, anxiety, spasticity – Limited but growing observational data.
Systematic reviews highlight mixed or low-quality evidence due to research limitations, but many patients report subjective improvements in quality of life.
Drug–Drug Interactions (DDIs) to Watch
Cannabinoids are metabolized through CYP450 pathways, leading to clinically significant DDIs: – Warfarin – Case reports of GI bleeding and elevated INR with CBD/THC. – Tacrolimus – Increased serum levels (up to 358%) reported with CBD. – Buprenorphine – Retrospective analysis showed serum levels 170% higher with cannabis use. – Methadone – Case reports of 117% increased concentrations with CBD. – Clozapine – Plasma levels rose 230% when cannabis was stopped abruptly. – Clobazam – Increased concentrations and sedation reported with CBD.
These interactions underscore the need for careful monitoring in patients who are often already on complex polypharmacy regimens.
Practical Considerations for Clinicians
– Start with CBD-dominant formulations, titrate slowly, and add THC cautiously if needed. – Titrate weekly or less frequently rather than every 4 hours or daily, as rapid titration may increase the risk of dizziness, confusion in older adults, and falls in frail patients. – Involve patients and families in shared decision-making, focusing on goals of care and risk–benefit balance. – Monitor closely for adverse effects (tachycardia, sedation, hypotension, neuropsychiatric symptoms) and DDIs. – Remember contraindications: age <25, pregnancy/lactation, history of psychosis, unstable cardiac disease, and concurrent use of strong CYP3A4 inhibitors.
Closing Thoughts
Cannabis is not a panacea, but when carefully integrated, it may serve as a valuable adjunct in palliative care. With FDA-approved cannabinoids paving the way, ongoing research and regulatory changes are critical to better define its role. For now, clinicians must remain cautious, evidence-informed, and patient-centered in exploring cannabis as part of comprehensive palliative care.
Key Takeaway: FDA-approved cannabinoids like dronabinol, nabilone, and Epidiolex demonstrate targeted benefits, but clinicians must weigh these against potential drug–drug interactions and limited high-quality evidence in palliative care.